AAN 2022 | Assessing remibrutinib in patients with relapsing MS
Xavier Montalban, MD, PhD, BA, Vall d’Hebron University Hospital, Barcelona, Spain, provides an overview of the Phase III REMODEL I and II trials (NCT05147220) of remibrutinib, a reversible BTK inhibitor, in patients with relapsing multiple sclerosis (MS). The two identical trials will assess the safety and tolerability of remibrutinib by comparing the BTK inhibitor with teriflunomide. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.
Disclosures
Dr Montalban has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.
